 |
|
“Our strategy remains the same: growth by acquisition and through organic means within Europe, and especially central and eastern Europe. We look for a balance between profit and growth” Petr Sulc, Zentiva |
PETR SULC, CHIEF financial officer of Czech pharmaceuticals producer Zentiva, has just returned to Prague after a two-day trip to New York. A packed schedule of 23 meetings in just 48 hours was testament to investor interest in his company, the first from the Czech Republic to have completed an IPO, and the beneficiary more recently of an investment by Sanofi-Aventis.
Access intelligence that drives action
To unlock this research, enter your email to log in or enquire about access
